Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 4Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Somatostatinoma 1Recurrent Malignant Solid Neoplasm 1Recurrent Lung Squamous Cell Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-hematologic Malignancy 1Neoplasms 1Multiple Myeloma 1Metastatic Castration-Resistant Prostate Cancer 1Lung Neoplasms 1Hematologic Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Burkitt Lymphoma 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Adenoma, Islet Cell 1

Interventions

durvalumab 7Carboplatin 7Docetaxel 6Paclitaxel 5Nivolumab 5talazoparib 4linifanib 4Cisplatin 4trifluridine tipiracil drug combination 3tremelimumab 3tislelizumab 3depatuxizumab 3ST 1481 3S 1 (combination) 3Panobinostat 3Gemcitabine 3zimberelimab 2toripalimab 2olaparib 2motesanib diphosphate 2mogamulizumab 2TAS-114 2Sorafenib 2Rifampin 2PM 01183 2Oxaliplatin 2MLN 8237 2Itraconazole 2Injections 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumors × sapanisertib × Clear all
NCT02197572 2023-01-23

Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors

Calithera Biosciences, Inc

Phase 1 Completed
44 enrolled 25 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡